Anna Patrikidou
Overview
Explore the profile of Anna Patrikidou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
70
Citations
815
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Duval L, Allignet B, Chevreau C, Gravis G, Mazza C, Gross-Goupil M, et al.
Clin Genitourin Cancer
. 2025 Mar;
23(2):102310.
PMID: 40037955
Introduction: Metastatic seminomatous germ cell tumors (mSGCT) are a rare form of cancer. Few studies focused on early relapse (<12 months) after first-line chemotherapy (ChT). We aimed to retrospectively evaluate...
2.
Patrikidou A, Oing C, Markellos C, Heidenreich A, Leao R, Nicolai N, et al.
Eur Urol Oncol
. 2025 Feb;
PMID: 39915218
The 2021 updated International Germ Cell Cancer Collaborative Group classification for seminomatous germ cell tumours confirmed and refined the original classification, introducing the notion that lactate dehydrogenase (LDH) elevation above...
3.
Patrikidou A, Saieva C, Lee-Ying R, Nuzzo P, El Zarif T, McClure H, et al.
Clin Genitourin Cancer
. 2024 Oct;
22(6):102230.
PMID: 39461026
Background: Androgen receptor signalling inhibitors (ARSIs) abiraterone acetate (AA) enzalutamide (Enza), are currently the standard first-line (L1) treatments for metastatic castration-resistant prostate cancer (mCRPC), and docetaxel (D) is reserved as...
4.
Gonnet P, Marinari E, Achard V, Schaffar R, Neyroud-Caspar I, May A, et al.
Cancers (Basel)
. 2024 Oct;
16(20).
PMID: 39456532
Background: Incidence of brain metastases is precisely unknown and there is no clear consensus on their management. We aimed to determine the incidence of brain metastases among patients with genito-urinary...
5.
Fotia G, Saieva C, Lee-Ying R, Patrikidou A, Nuzzo P, Zanardi E, et al.
Clin Genitourin Cancer
. 2024 Aug;
22(5):102185.
PMID: 39217072
Background: Managing metastatic castration-resistant prostate cancer (mCRPC) in men aged ≥ 75 is challenging due to limited data. Regardless of age, in real-world clinical practice, most mCRPC still derive from...
6.
Oing C, Rescigno P, Paffenholz P, Heinzelbecker J, Patrikidou A, Matulewicz R, et al.
Eur Urol Focus
. 2024 Aug;
10(3):361-363.
PMID: 39095218
Treatment de-escalation strategies in patients with seminoma with retroperitoneal metastases are being investigated in ongoing clinical trials. Primary retroperitoneal lymph node dissection conducted by expert surgeons may avoid any cytotoxic...
7.
Mathiot L, Baldini C, Letissier O, Hollebecque A, Bahleda R, Gazzah A, et al.
Curr Oncol Rep
. 2024 Jul;
26(10):1236-1248.
PMID: 39066847
Purpose Of Review: Antibody-drug conjugates (ADCs) offer a promising path for cancer therapy, leveraging the specificity of monoclonal antibodies and the cytotoxicity of linked drugs. The success of ADCs hinges...
8.
Grisay G, Turco F, Litiere S, Fournier B, Patrikidou A, Gallardo E, et al.
Front Oncol
. 2024 May;
14:1391825.
PMID: 38779087
The landscape of treating metastatic prostate cancer has evolved with the addition of Androgen Receptor pathway inhibitor (ARPI) to Androgen Deprivation Therapy (ADT), significantly improving survival rates. However, prolonged use...
9.
Mokbel S, Baciarello G, Lavaud P, Omlin A, Calabro F, Cathomas R, et al.
Cancers (Basel)
. 2024 Apr;
16(8).
PMID: 38672547
Background: Immune checkpoint inhibitors (ICIs) improve overall survival (OS) in advanced/metastatic urothelial cancer (a/mUC) patients. Preliminary evidence suggests a prognostic role of inflammatory biomarkers in this setting. We aimed to...
10.
Flippot R, Telli T, Velev M, Flechon A, De Vries-Brilland M, Turpin L, et al.
Eur Urol Oncol
. 2024 Apr;
7(5):1132-1140.
PMID: 38664139
Background: Both cabazitaxel and lutetium-177 prostate-specific membrane antigen (Lu-PSMA) improve survival in metastatic castration-resistant prostate cancer (mCRPC) after an androgen receptor pathway inhibitor and docetaxel, but there are limited data...